Teachers Retirement System of The State of Kentucky Decreases Holdings in Repligen Co. (NASDAQ:RGEN)

Teachers Retirement System of The State of Kentucky lowered its position in Repligen Co. (NASDAQ:RGEN) by 2.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,408 shares of the biotechnology company’s stock after selling 450 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Repligen were worth $2,442,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of RGEN. Champlain Investment Partners LLC lifted its holdings in shares of Repligen by 149.0% in the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after acquiring an additional 850,345 shares during the last quarter. Bank of New York Mellon Corp raised its position in Repligen by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock worth $172,749,000 after purchasing an additional 237,884 shares during the period. Conestoga Capital Advisors LLC lifted its stake in Repligen by 26.7% in the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock worth $119,363,000 after purchasing an additional 199,322 shares during the last quarter. Thrivent Financial for Lutherans boosted its position in Repligen by 6.1% during the third quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock valued at $95,037,000 after buying an additional 36,773 shares during the period. Finally, DF Dent & Co. Inc. grew its stake in shares of Repligen by 31.0% during the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after buying an additional 139,615 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Repligen Price Performance

Shares of Repligen stock opened at $156.41 on Monday. The business has a 50 day moving average of $142.66 and a 200 day moving average of $141.59. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $211.13. The company has a market cap of $8.76 billion, a PE ratio of -422.73, a P/E/G ratio of 4.64 and a beta of 0.96. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. The business had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.23 EPS. As a group, equities research analysts forecast that Repligen Co. will post 1.54 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on RGEN shares. Wells Fargo & Company started coverage on Repligen in a report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price for the company. Wolfe Research began coverage on Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating for the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Finally, StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a report on Friday, November 22nd. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Repligen has an average rating of “Moderate Buy” and an average price target of $190.25.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.